Updated results from the INWORKS study “show the importance of adherence to the basic principles of radiation protection,” according to researchers.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Strengthening health care access and quality … will be paramount for improving clinical outcomes and slowing projected trends,” researchers wrote.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Binod Dhakal, MD, MS, provides an overview of the CARTITUDE-4 trial, including its methods, design, and inclusion criteria.

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

It was once the standard of care for patients with relapsed or refractory multiple myeloma. Overall response rate (ORR): percentage of patients who have a partial response to treatment (tumor ...